| Literature DB >> 15450123 |
Shiliang Liu, Roy West, Edward Randell, Linda Longerich, Kathleen Steel O'connor, Helen Scott, Marian Crowley, Angeline Lam, Victor Prabhakaran, Catherine McCourt.
Abstract
BACKGROUND: Periconceptional use of vitamin supplements containing folic acid reduces the risk of a neural tube defect (NTD). In November 1998, food fortification with folic acid was mandated in Canada, as a public health strategy to increase the folic acid intake of all women of childbearing age. We undertook a comprehensive population based study in Newfoundland to assess the benefits and possible adverse effects of this intervention.Entities:
Year: 2004 PMID: 15450123 PMCID: PMC524178 DOI: 10.1186/1471-2393-4-20
Source DB: PubMed Journal: BMC Pregnancy Childbirth ISSN: 1471-2393 Impact factor: 3.007
Framework for a two phase, multi site study to examine the effects of food fortification with folic acid
| Content | Study objective | Sample ** | Location |
| I. Rates of NTDs | Determine rate of NTD-affected pregnancies, pre and post fortification | Newfoundland population | Newfoundland |
| II. Dietary assessment* | Determine dietary intake of folate, pre and post Fortification | A) Non-pregnant women of childbearing age (19–44 years), not taking supplements containing folic acid; | St. John's, Rural Newfoundland |
| III. Blood analysis* | Determine blood folate and vitamin B12 status, pre and post fortification | B) Seniors (65 years or older) not taking supplements containing folic acid or B12 supplement and not diagnosed with anaemia. | St. John's, Rural Newfoundland |
| IV. Knowledge and intake of folic acid supplements | Determine knowledge and consumption of folic acid supplements, pre and post fortification | Non-pregnant women of childbearing age (19–44 years) | St. John's, Rural Newfoundland |
* The same sample of women and seniors are analyzed in Components II and III.
** Sampling was done separately for Phases I and II.
Figure 1Rates of NTDs in Newfoundland and Labrador, 1976 to 2001 (3-year moving average rates) *The rate for 1976 is a 2-yr average based on data for 1976 and 1977 and the rate for 2001 is a 2-yr average based on data for 2000 and 2001.
Annual rates of neural tube defects (NTDs) in Newfoundland and Labrador before folic acid supplementation (1991–1993), prior to folic acid fortification (1994–1997) and after fortification (1998–2001)
| Period | No. of cases of NTDs | Total no. of births* | Rate per 1,000 births | ||
| In live births and stillbirths | In terminated pregnancies | Total | |||
| Pre-supplementation | |||||
| 1991–1993 | 50 | 40 | 90 | 20,711 | 4.35 |
| Pre-fortification | |||||
| 1994–1997 | 53 | 50 | 103 | 23,592 | 4.37 |
| Post-fortification | |||||
| 1998–2001 | 8 | 11 | 19 | 19,816 | 0.96 |
* The total number of births includes live births, stillbirths and terminations for an NTD.
Laboratory data (geometric mean and 95% confidence interval) for young women participants (age 19–44 years) in Phase I and Phase II
| Characteristic | Phase I | Phase II | p value † |
| Total participants (n) | 233 | 204 | |
| Serum folate (nmol/L) | 13.5 (12.9 – 14.1) | 18.1 (17.3 – 18.9) | <0.001 |
| RBC folate (mol/L) | 625 (601 – 649) | 818 (784 – 854) | <0.001 |
| Plasma HCY (μmol/L) | 10.2 (9.8 – 10.7) | 9.2 (8.8 – 9.6) | 0.001 |
| Serum vitamin B12 (pmol/L) | 177 (169 – 186) | 200 (190 – 211) | 0.02 |
| Plasma MMA (μmol/L) | 0.18 (0.17 – 0.19) | 0.21 (0.19 – 0.22) | 0.008 |
† P value for the difference between Phase I and Phase II is based on a non-parametric Mann-Whitney U test.
RBC denotes red blood cell, HCY denotes homocysteine, and MMA refers to methylmalonic acid.
Laboratory data (geometric mean and 95% confidence interval) for senior participants (age 65 years or over) between Phase I and Phase II
| Characteristic | Phase I | Phase II | P value ‡ |
| Total participants (n) | 202 | 186 | |
| Serum folate (nmol/L) | 14.8 (14.0 – 15.6) | 23.0 (22.0 – 24.1) | <0.001 |
| RBC folate (mol/L) | 745 (713 – 779) | 916 (873 – 961)† | <0.001 |
| Plasma HCY (μmol/L) | 13.6 (13.0 – 14.2)† | 12.3 (11.7 – 12.9)† | 0.001 |
| Serum vitamin B12 (pmol/L) | 183 (173 – 194) | 216 (202 – 231) | <0.001 |
| Plasma MMA (μmol/L) | 0.24 (0.22 – 0.27)† | 0.26 (0.24 – 0.28) | 0.229 |
† The Komogorov-Smirnov test showed that the log transformed data were non-normal (p < 0.05).
‡ P value for the difference between Phase I and Phase II is based on a non-parametric Mann-Whitney U test.
RBC denotes red blood cell, HCY denotes homocysteine and MMA refers to methylmalonic acid.